Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After LASIK: a Randomized Clinical Trial

Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After Laser in Situ Keratomileusis: A Randomized Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01506635

Enrollment

Registered

2012-01-10

Start date

2010-03-31

Completion date

2010-12-31

Last updated

2012-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopic Regression

Brief summary

In this randomized controlled clinical trial, we compare the effects of timolol versus placebo for treatment of myopic regression after LASIK

Interventions

DRUGTimolol

DRUGPlacebo

artificial tear twice a day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with myopic regression equal or more than 0.5 D with minimum age of 20 years, * cylinder ≤ -1.00 D, * corrected distance visual acuity (CDVA) of at least 20/40 were included.

Exclusion criteria

* Patients with a history of previous ocular surgery, * keratoconus or any ectatic corneal disorder, * keratoconus suspect by topography, * preoperative corneal opacity, * any corneal dystrophies, * presence of pterygium, * retinal disorders, * collagen vascular disorders, * diabetes mellitus, * glaucoma, * cataract, * pregnancy, * breast feeding * systemic corticosteroid therapy were excluded.

Design outcomes

Primary

Measure	Time frame	Description
Spherical Equivalent	spherical equivalent at month 6	Effect of timolol use in timolol group will be compared with placebo group at month 6. Moreover, the changes of intragroup spherical equivalent will be assessed in both group 6 months after timolol application.

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026